EUVIMEDEUVIMED entdecken
Crossref

Endoscopic treatment for early duodenal papillary carcinoma: long‐term outcomes

Yingyu Wang, Hayat Khizar iD, Haibin Zhou, Hangbin Jin, Qifeng Lou, Xiaofeng Zhang, Jianfeng Yang

Journal of Gastroenterology and Hepatology · 2024-07 · 39 (7) · 1367-1373

DOI: 10.1111/jgh.16546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 25.03.2024. Verfasst von Yingyu Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hangzhou First People's Hospital, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Duodenal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project, Zhejiang Province's 2024 Key R&D Plan Project, Hangzhou Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim This study aims to determine whether endoscopic papillectomy (EP) is a safe and effective treatment for early duodenal papillary carcinoma with long‐term follow‐up.

Methods

From June 2012 to September 2022, 48 patients with early duodenal papilloma carcinoma who received endoscopic treatment were included. The histological types, percentage of complete resections, postoperative residuals, adverse events, and recurrences were evaluated.

Results

EP was successful in all patients; 46 were lumped, and two were fragmented, with a 95.8% intact removal rate (46/48). The preoperative biopsy pathological positive rate was 70.8% (34/48). The incidence of early postoperative adverse events (within 1 month after EP) were 16.7% (8/48), including four cases of acute pancreatitis, three cases of delayed bleeding, and one case of acute cholangitis. In addition, 4.2% (2/48) of the late adverse events were bile duct stenosis. After 6 months, the postoperative residual rate was 0%. The median time to recurrence was 17.5 months, and the postoperative recurrence rate was 16.7% (8/48) in patients treated with radiofrequency ablation. The median progression‐free survival was 18.6 months (95% CI, 12.1–25.1), and the median overall survival was 121.5 months (95% CI, 105.6–120.9).

Conclusions

EP is a safe and efficient alternative therapy for early duodenal papillary carcinoma. Endoscopic follow‐up and treatment are essential because of the potential for recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Duodenal NeoplasmsHumansMaleFemaleMiddle AgedAgedTreatment OutcomeTime FactorsCarcinoma, PapillaryFollow-Up StudiesAdultNeoplasm Recurrence, LocalPostoperative ComplicationsAged, 80 and over

Stichwörter der Autor:innen

Endoscopic papillectomyRFAduodenal papillary carcinomalong‐term follow‐up

Autor:innen und Institutionen

  • Department of Gastroenterology, Hangzhou First People's Hospital, Hangzhou, Zhejiang, China.
  • Department of Gastroenterology, Yuhang First People's Hospital, Hangzhou, Zhejiang, China.
  • Department of Oncology, The Fourth Affiliated Hospital, International Institute of Medicine, Zhejiang University School of Medicine, Hangzhou, China.
  • Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou, Zhejiang, China.
  • Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, Zhejiang, China.
  • Hangzhou Institute of Digestive Diseases, Hangzhou, Zhejiang, China.

ORCID-Profile: Hayat Khizar

Förderung

  • Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project
  • Zhejiang Province's 2024 Key R&D Plan Project
  • Hangzhou Science and Technology Commission
  • Construction Fund of Medical Key Disciplines of Hangzhou
  • Hangzhou Medical and Health Technology Project
  • Zhejiang Medical Health Science and Technology Program

Zitieren

APA

Wang, Y., Khizar, H., Zhou, H., Jin, H., Lou, Q., Zhang, X., & Yang, J. (2024). Endoscopic treatment for early duodenal papillary carcinoma: long‐term outcomes. Journal of Gastroenterology and Hepatology, 39(7), 1367-1373. https://doi.org/10.1111/jgh.16546

Vancouver

Wang Y, Khizar H, Zhou H, Jin H, Lou Q, Zhang X, et al. Endoscopic treatment for early duodenal papillary carcinoma: long‐term outcomes. Journal of Gastroenterology and Hepatology. 2024;39(7):1367-1373. doi:10.1111/jgh.16546

BibTeX
@article{Wang2024,
  author = {Wang, Yingyu and Khizar, Hayat and Zhou, Haibin and Jin, Hangbin and Lou, Qifeng and Zhang, Xiaofeng and Yang, Jianfeng},
  title = {Endoscopic treatment for early duodenal papillary carcinoma: long‐term outcomes},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  volume = {39},
  number = {7},
  pages = {1367--1373},
  doi = {10.1111/jgh.16546}
}
Kostenlos starten →